Inactive Instrument

Press Releases Oncolytics Biotech Inc. Toronto S.E.

Equities

CA6823101077

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Oncolytics Biotech Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting	Apr. 26	AQ
Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting	Apr. 25	AQ
Oncolytics Biotech : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 15, 2024 MANAGEMENT INFORMATION CIRCULAR - Form 6-K	Apr. 12	PU
Oncolytics Biotech Advances toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA	Apr. 12	AQ
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA	Apr. 11	PR
Oncolytics Biotech to participate in a Panel Presentation at Canaccord Genuity s Horizons in Oncology Virtual Conference	Apr. 03	AQ
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning	Mar. 06	NE
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights	Mar. 04	AQ
Oncolytics Biotech Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference	Feb. 29	AQ
Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments	Feb. 15	NE
Oncolytics Biotech Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort	Feb. 15	AQ
Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort	Feb. 14	PR
Oncolytics Biotech Appoints Patricia S. Andrews to its Board of Directors	Jan. 10	AQ
Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors	Jan. 09	PR
Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024	Jan. 04	AQ
Oncolytics Biotech and SOLTI Present Positive Translational Data at SABCS	Dec. 08	AQ
Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS	Dec. 07	PR
Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy	Nov. 09	PR
Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep	Nov. 09	PR
Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC	Nov. 03	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Oncolytics Biotech Inc. Toronto S.E.

Equities

CA6823101077

Press Releases

Filters